Anti-fibrosis therapy and diabetic nephropathy (Q38014361)

27 August 2017

title

Anti-fibrosis therapy and diabetic nephropathy (English)

1 reference

27 August 2017

Anil Karihaloo

1 reference

27 August 2017

publication date

1 August 2012

1 reference

27 August 2017

published in

Current diabetes report

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

414-422

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Diabetic nephropathy: important pathophysiologic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Pirfenidone is renoprotective in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Circulating fibrocytes: cellular basis for NSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

RAGE and the pathogenesis of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Nuclear hormone receptors in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Is diabetic nephropathy an inherited complication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

MicroRNA‐451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Is type II diabetes mellitus a disease of the innate immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Why is proteinuria an ominous biomarker of progressive kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

How does proteinuria cause progressive renal damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Renal and retinal effects of enalapril and losartan in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Low-density lipoprotein stimulates the expression of macrophage colony-stimulating factor in glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Pirfenidone: in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Antifibrotic activities of pirfenidone in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Signaling mechanisms in the regulation of renal matrix metabolism in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Transforming growth factor-β/Smad signalling in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

TGF-beta impairs renal autoregulation via generation of ROS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Next-generation sequencing identifies TGF-β1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Cell surface receptors in lysophospholipid signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

LPA1 receptor activation promotes renal interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Ezetimibe ameliorates early diabetic nephropathy in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Activation of Bone Morphogenetic Protein 4 Signaling Leads to Glomerulosclerosis That Mimics Diabetic Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Rho kinase inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Rho kinase inhibition: a new approach for treating diabetic nephropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Activated protein C inhibits pancreatic islet inflammation, stimulates T regulatory cells, and prevents diabetes in non-obese diabetic (NOD) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Alteration in the phenotype of macrophages in the repair of renal interstitial fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Macrophages and renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Distinct macrophage phenotypes contribute to kidney injury and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Murine models of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Investigational drugs for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-012-0290-7

Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression

21 January 2018

1 reference

12 December 2020

Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury

1 reference

12 December 2020

Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice

1 reference

12 December 2020

Telmisartan in the management of diabetic nephropathy: a contemporary view

1 reference

12 December 2020

Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients

1 reference

12 December 2020

Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency

1 reference

12 December 2020

Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis

1 reference

12 December 2020

Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation.

1 reference

12 December 2020

Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis

1 reference

12 December 2020

Exogenous activated protein C inhibits the progression of diabetic nephropathy

1 reference

12 December 2020

Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

1 reference

12 December 2020

LDL stimulates mesangial fibronectin production and chemoattractant expression

1 reference

12 December 2020

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition in human renal proximal tubular epithelial cells.

1 reference

12 December 2020

The significance of plasma lysophospholipids in patients with renal failure on hemodialysis

1 reference

12 December 2020

Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes

1 reference

12 December 2020

Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy

1 reference

12 December 2020

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')

1 reference

12 December 2020

Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes

1 reference

12 December 2020

Renal interstitial expansion in insulin-dependent diabetes mellitus

1 reference

12 December 2020

Fibrosis and atrophy in the renal allograft: interim report and new directions

1 reference

12 December 2020

Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II

1 reference

12 December 2020

The role of lipids in the pathogenesis of glomerulosclerosis in the rat following subtotal nephrectomy

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.1007/S11892-012-0290-7

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1038227944

0 references

1 reference